Latest News
All Times Eastern
- Will the ECB hike rates or not? Decision set to be cliff hanger as eurozone sentiment indicators deteriorate
- DocuSign shares rise after earnings, and other movers
- Barron's DocuSign, Apple, Smartsheet, Guidewire Software, RH, and More Stock Market Movers
- U.S. stock futures lean higher after difficult week on Wall Street
- Barron's Banks Are Stuck in a Rut. A Buyout Wave Could Be Building.
- Barron's High-Quality Dividend Stocks Are on Sale. Now Is the Time to Buy.
- Barron's Why Walt Disney Could Cave First in Its Cable Standoff With Charter
- Barron's 5 Federal Deficit Myths, Explained
- Barron's Walgreens Is Looking for a New CEO. Why That Could Make the Stock a Winner.
- Barron's Active Funds Rocked August. Passive Is Grabbing the Year.
to be replaced
Novo Nordisk A/S ADR
NVOUS
$
0.30
0.15%
Premarket
$
195.68
Before Hours Volume:
13.18K
| Close | Chg | Chg % |
|---|---|---|
| $195.38 | 4.13 | 2.16% |
Volume: 3.22M
65 Day Avg: 1.54M
192.14
Day Range
197.54
95.02
52 Week Range
197.54
Partner Center
Your Watchlists
Recently Viewed Tickers
Overview
NVO Overview
Key Data
- Open $192.14
- Day Range 192.14 - 197.54
- 52 Week Range 95.02 - 197.54
- Market Cap $424B
- Shares Outstanding 1.72B
- Public Float 1.7B
- Beta 0.54
- Rev. per Employee $521.88K
- P/E Ratio 46.41
- EPS $4.21
- Yield 0.75%
- Dividend $0.88
- Ex-Dividend Date Aug 18, 2023
- Short Interest 2.05M 08/15/23
- % of Float Shorted 0.12%
- Average Volume 1.54M
Performance
| 5 Day |
|
| 1 Month |
|
| 3 Month |
|
| YTD |
|
| 1 Year |
|
Analyst Ratings
Number of Ratings 27
Full Ratings
Recent News
Biotech and Pharma Eli Lilly and Other Pharma Stocks Are Ignoring Medicare’s 10 Drug List
Biotech and Pharma Novo Nordisk’s Wegovy Helped Heart-Failure Patients. What’s Next?
Biotech and Pharma Eli Lilly Rises Again as Stock Upgraded Following Mounjaro Sales Surge
The 3 Best Stocks to Buy Now: September 2023
on InvestorPlace.com
Why Novo Nordisk Stock Topped the Market on Thursday
on Motley Fool
Unveiling Novo Nordisk A/S (NVO)'s Value: Is It Really Priced Right? A Comprehensive Guide
Unveiling Novo Nordisk A/S (NVO)'s Value: Is It Really Priced Right? A Comprehensive Guide
on GuruFocus.com
Is Novo Nordisk Stock a Buy Now?
on Motley Fool
3 Nasdaq Stocks to Sell in September Before They Crash & Burn
on InvestorPlace.com
7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue Growth
on InvestorPlace.com
Novo Nordisk Unusual Options Activity
on Benzinga.com
Top 3 Pharma Stocks to Boost Your Portfolio
on StockNews.com
Could CVS Make a Copy of Ozempic?
on Motley Fool
8 Pharma Stocks Affected by New Drug Price Negotiation Rules
on Motley Fool
The 3 Most Promising Healthcare Stocks to Own Now
on InvestorPlace.com
Novo Nordisk A/S ADR
Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.
Competitors
| Name | Chg % | Market Cap |
|---|---|---|
| Eli Lilly & Co. | $531.56B | |
| Sanofi ADR | $132.15B | |
| Bristol Myers Squibb Co. | $124.66B | |
| Pfizer Inc. | $194.05B | |
| Roche Holding AG Part. Cert. | $228.63B |